Product Description
Mechanisms of Action: ADRB1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Germany | Ireland | Italy | New Zealand | Portugal | Taiwan | Turkey
Approved Indications: None
Known Adverse Events: None
Company: Weill Medical College of Cornell University
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Heart Failure, Chronic|Heart Failure, Diastolic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04757584 |
K76AG064428 | P4 |
Completed |
Heart Failure, Chronic|Heart Failure, Diastolic |
2023-04-28 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT04767061 |
P19-000458 | P4 |
Completed |
Heart Failure, Diastolic|Heart Failure, Chronic |
2022-04-28 |
2024-10-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|
